spacer
Life Extension
 

Life Extension is a global authority on nutrition, health and wellness

as well as a provider of scientific information on anti-aging supplements and therapies. We supply only the highest quality nutritional supplements, including minerals, vitamins, herbs and hormones.

Access your account today: Login        Learn about our membership benefits

translation by SYSTRAN  
Life Extension Annual Super Sale - Shop Now!
 
Health Concerns

Sjögren's Syndrome

References

Baudouin C. The pathology of dry eye. Surv Ophthalmol . 2001 Mar;45 Suppl 2:S211–S20. Review.

Baudouin C, Pisella PJ, et al. [Current treatments of xerophthalmia in Sjögren's syndrome] Rev Med Interne . 2004 May;25(5):376–382. Review. French.

Bombardieri M, Barone F, et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther . 2004;6(5):R447–R456.

Brito-Zeron P, Ramos Casals M, et al. Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine ( Baltimore ). 2005 Mar;84(2):90–97.

Carsons S. The New Sjögren's Syndrome Handbook 1998 . New York : Oxford University Press.

Derk CT, Vivino FB. A primary care approach to Sjögren's syndrome: helping patients cope with sicca symptoms, extraglandular manifestations. Postgrad Med . 2004 Sep;116(3):49–54, 59, 65. Review.

Fife RS, Chase WF, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med . 2002 Jun 10;162(11):1293–1300.

Gerli R, Bertotto A, et al. Anti-CD3 and anti-CD2-induced Tcell activation in primary Sjögren's syndrome. Clin Exp Rheumatol . 1989 Sep-Oct;7(Suppl. 3):S129-S134.

Glaser R, Rabin B, et al. Stress-induced immunomodulation: implications for infectious diseases. JAMA . 1999 Jun 23–30;281(24):2268–2270.

Hadden JW, Hadden EM. Therapy of secondary T-cell immunodeficiencies with biological substances and drugs. Med Oncol Tumor Pharmacother . 1989;6(1):11.

Harbige LS. Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc . 1998 Nov;57(4):555–562.

Hayashi Y, Arakaki R, et al. Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr Opin Rheumatol . 2004 Sep;16(5):522–526. Review. Erratum in: Curr Opin Rheumatol . 2004 Nov;16(6):753.

Horrobin DF. Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses 1981 Sep;7(9):1211–1220.

Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjögren's syndrome. Med Hypotheses . 1984 July;14(3):233–247.

Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol . Suppl. 1986;61:242–245.

Ishimaru N, Saegusa K, et al. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis. Am J Pathol . 1999 Jul;155(1):173–181.

Klimberg VS, Salloum RM, et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg . 1990 Aug;125(8):1040–1045.

Kouttab NM , Prada M, et al. Thymomodulin: biological properties and clinical applications . Med Oncol Tumor Pharmacother . 1989;6(1):5.

Kujawa A, Rozycki R. [Immunological phenomenons in the pathology of the tear film. Is cyclosporine the turn point in the Sjögren's syndrome treatment? Preliminary report] Klin Oczna . 2004;106(3 Suppl):489–491. Polish.

Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis . 2005 Jul;64(7):1062-4.

Lynge Pedersen AM, Bardow A, et al. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren's syndrome. BMC Clin Pathol . 2005 Mar 1;5(1):4

Mahoney EJ, Spiegel JH. Sjögren's disease. Otolaryngol Clin North Am . 2003 Aug;36(4):733–745. Review.

Mariette X. Current and potential treatments for primary Sjögren's syndrome. Joint Bone Spine . 2002 Jun;69(4):363–366. Review.

Nusair S, Rubinow A. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum . 1999 Jun;28(6):360–367.

Oxholm P, Manthorpe R, et al. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. Scand J Rheumatol . 1986;15(2):103–108.

Oxholm P, Asmussen K, et al. Essential fatty acid status in cell membranes and plasma of patients with primary Sjögren's syndrome. Correlations to clinical and immunologic variables using a new model for classification and assessment of disease manifestations. Prostaglandins Leukot Essent Fatty Acids . 1998 Oct;59(4):239–245.

Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol . 2005 Apr;98(4):1154–1162.

Rousso E, Noel E, et al. [Recurrent facial palsy, primary Gougerot-Sjögren's syndrome and vitamin B12 deficiency] Presse Med . 2005 Jan 29;34(2 Pt 1):107–108. French.

Ship JA, Fox PC, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res . 1999 Aug;19(8):943–951.

Sjögren's Syndrome Foundation. Available at: www.Sjögren's.org . Accessed October 10, 2005.

Stevenson HA, Jones ME, et al. UK patients with primary Sjögren's syndrome are at increased risk from clinical depression. Gerodontology . 2004 Sep;21(3):141–145.

Talal N. Overview of Sjögren's syndrome. J Dent Res . 1987 Feb;66(Spec No):672–674.

Tishler M, Paran D, et al. Allergic disorders in primary Sjögren's syndrome. Scand J Rheumatol . 1998;27(3):166–169.

Tsubota K, Monden Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol . 1999 Jul;83(7):767–770.

Valtysdottir ST , Wide L, et al. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol . 2001 Jun;28(6):1259–1265.

Venables PJ. Sjögren's syndrome. Best Pract Res Clin Rheumatol . 2004 Jun;18(3):313–329. Review.

Wilson JL. Thymus extracts: an international literature review of clinical studies 1999. Available at http://www.hepatitiscfree.com/thymus_article2.html . Accessed October 10, 2005.

Wu AJ. The oral component of Sjögren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep . 2003 Aug;5(4):304–310.

Yamada S, Mori K, et al. Interferon alfa treatment for Sjögren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry . 2005 Apr;76(4):576–578.

Zhang NZ, Shi QS, et al. [Epidemiological studies on primary Sjögren's syndrome] Zhonghua Nei Ke Za Zhi . 1993 Aug;32(8):522–524. Chinese.

column header
Sign Up for Life Extension's FREE email newsletter Products
Magazine
Abstracts
spacer
Vital Greens Mix
Network Solutions SecuredBetter Business Bureau Accredited BusinessLife Extension Track Record5-Star Rated Fish Oil SupplementLife Extension Royal Treatment Customer ServiceLearn About our VIP AutoShip ProgramCustomer Satisfaction GuaranteedDirect Marketing Association Member

Home | Membership | Products | Magazine | Health Concerns | News | About Us | Legal Notices | Privacy Policy | Site Map


All Contents Copyright © 1995-2009 Life Extension Foundation® All rights reserved.

*These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.